Home Companies Catalysts Deep Dives
Airsupra albuterol/budesonide APPROVED
Drug Profile
ModalityInhaler
RouteINHALATION
Therapy AreaR&I
Launch2023-01-11
US LOE2028-01-01
Peak Sales Est$1000M
Formulations[{"id":"airsupra-inhaler","doses":"75/4.5 mcg, 150/9 mcg","route":"Inhaled","setting":"PATIENT_SELF"
Companies
AZN (ORIGINATOR)100%
Mechanism: ICS/SABA combination
Expert: Fixed-dose combination of inhaled corticosteroid (budesonide) and short-acting beta-agonist (albuterol) for as-needed rescue and anti-inflammatory therapy.
Everyday: A rescue inhaler combining anti-inflammatory steroid with quick-relief bronchodilator for asthma attacks.
Targets: []
Revenue History
PeriodRevenue ($M)
2024$92M
Q1 2025$45M
Programs (1)
IndicationStageKey StudyRegional Status
Asthma (PRN)APPROVEDMANDALA[{"stage":"APPROVED","region":"US","approval_date":"2024-01-09"}]
Notes
Rescue inhaler.
Data from Supabase · Updated 2026-03-24